WO2009101453A1

WO2009101453A1 - Compositions and methods of cure and prophylaxis of hiv/aids and related syndromes

Info

Publication number: WO2009101453A1
Application number: PCT/GH2008/000003
Authority: WO
Inventors: Ojo Emmanuel Oluwaseyi Sunday
Original assignee: Ojo Emmanuel Oluwaseyi Sunday
Priority date: 2008-02-13
Filing date: 2008-12-09
Publication date: 2009-08-20

Abstract

This invention provides a composition and methods for cure and vaccine of HIV/AIDS, wherein the composition is comprised of a newly discovered organic molecule called Fungocyneo F & B (or ViracombR Irreversible Inhibitor, VII) compounded with diplopod protein, Anthoclesta djalonesisx and carbon of Anchomanes difformis administered intramuscularly, intravenously and orally as an effective inhibitor of HIV coat protein bound to human receptor cell, inhibitor of reverse transcriptase, protease and integrase of HIV and eliciting an immune response to any immunodeficiency in human beings. This new composition also deals with protozoan infections and diabetes.

Description

COMPOSITIONS AND METHODS OF CURE AND PROPHYLAXIS OF HIV/AIDS AND RELATED SYNDROMES

DESCRIPTION FIELD OF INVENTION

This new invention relates to a cure and prophylactic vaccine against HIV-1 and HIV-2. It is a clear departure from the traditional recombination or mutating of viral genome. It is a discovery of a new giant molecular mass which is combined with certain proteins and carbohydrates to manufacture a very safe and effective therapeutic and prophylactic HIV/AIDS vaccine against all strands and variants of HIV-1 and HIV-2. No HIV viral genome is used in the invention.

BACKGROUND OF INVENTION

The prior arts in this filed include the following: Viracept, Aviranz, Lamividen, Ritonavir R, Efavirenz, Nevirapine, Zidovudine, Zodovudine Stavidine, lsentress and many other vaccine candidates that have failed.

Unlike most of these prior arts which are Anti-Retroviral Drugs, for management of HIV and attacking the opportunistic infections. They do not make a claim of cure or prophylaxis.

This new composition, however, functions in the body as prophylaxis and cure, eliminating the virus from the system, and preventing it virus from integrating with the host cell by destroying and altering it's genome.

This invention is a clear departure from the traditional recombination or mutating of viral genome to produce a vaccine. This is a discovery of a new giant molecular mass, which is combined with certain proteins and carbohydrates to manufacture a very safe and effective therapeutic and prophylactic HIV/AIDS vaccine against ail strands and variants of HIV-1 and HIV-2. Unlike in other prior arts, no HlV viral genome is used in this new invention.

This invention called Viracomb™ is an antigen that stimulates the body protein to produce similar antigen, which recognizes incoming HIV-1 and HIV- 2 invaders, primes them and alters their memory and becomes a permanent antibody. As a therapeutic vaccine, Viracomb™ permanently stops HIV-1 and HIV-2 viral replication and mutation processes and deactivates all viral metabolisms. This is a multi-viral combater developed

The active substance is capable of re-synthesizing itself in the body with the help of Anchomanes-difformis molecule.

The method of combining the composition and their functions are newly discovered and titled by the inventor.

For instance: We have antho-C, Ancho-C-DPD protein and Tropica lgboemma a newly discovered molecule, which is the active substance. Its characteristics are studied and combined according to their strength in useful proportion.

THE LEADING EDGE IN VIRACOMB HIV/AIDS VACCINES

Viracomb™ Vaccine is not susceptible to anti-vector immunity as some of the prior arts in this field. The functions of Viracomb™ far exceed the actions of PB DNA Vaccine. Viracomb™ vaccine initiates almost 500% of CD4-T cell responses and almost 300% responses of CD8-T cell responses. The responses of these T-cells depend on the dosage administered. The adequate administration of the doses induces highest level of T-cell responses even when used for curative management. The substances in this new invention suppress the actions of HIV I & Il from 100% to almost 5%, permanently stops the viral replication processes and deactivates viral metabolism. Some major points about Viracomb™ are:

1. It induces highest level of insulin in the body;

2. It has the advantage of targeting efficient gene delivery and high potency.

3. Viracomb™ also elicits high immune responses against almost all protozoan, viral and other infectious diseases.

This invention relates to an anti: CD8 killer cells, inhibitor of HIV protease, inhibitor of HIV integrase protein, inhibitor of HIV coat protein molecules which normally binds to receptor cell or T-cell groups, anti CYP450, SD 120 enzyme groups, Anti-Intestinal infectious bacteria caused by Human Immune Viruses. The invention is known to have certain organic properties which active molecule is an extract from Tropica lgboemma A and B species which shows show good adhesion to human and animal genetic component e.g. DNA, receptor cells (T - cells), blood plasma, lymphocytes and all immune cell groups. By virtue of the A and B carbon and protein species in the drug, it has lent itself to both therapeutic and prophylactic applications.

The problems addressed by the present invention is to provide anti Human Immune Virus and Anti AIDS Agent, strong integrase and protease Inhibitor which is an effective vaccine against all strains of protozoan infections, a therapy and cure of diabetes in human beings or animals, therapeutic and prophylactic treatment of impaired immune cells and prevention of further damage of immune cells and invasion of new deadly viruses. It is also intended to cure gastro intestinal disorders, to prevent future occurrence and infections by viruses and other gram positive pathogens and protozoan infections.

SUMMARY OF THE INVENTION

To this end, the present Invention relates to an anti cellular and DNA infections agents which is capable of displacing pathogenic viruses, bacteria, protozoa and Plasmodia from the liver, cells and genetics components, gastric cells and or intestinal cells. It is a biological scientific combination of anthoclesta carbon, anchomanes carbon, Tropica lgboemma A and B carbon and protein, Diplopoda bacterial protein strain for it is ability to produce this agent of synthetic, metabolic and catalytic enzymes and to a composition containing an effective quantity of the combined extracts in an intramuscular and ingestible support, more particularly a pharmaceutically acceptable support. DETAILED DESCRIPTION OF THE INVENTION

It has been discovered that certain species of organic plants particularly Tropica lgboemma A and B carbon and protein are capable of destroying the protein coats of HIV which normally bind to human receptor cells. Integrase, reverse transcriptase, protease inhibitors, and protein components of Human Immune viruses and protozoa, displacing them from the cells, intestines and liver to which they adhere. It has been found that the drug in question has the ability to produce an agent like: MRNAS Enzymes, H5H6, REV 3, RAD 30 NTG1 NTG2, OGG1, APN1 , APN2, which helps to repair DNA, produce healthy DNA and alter viral genome by inducing the body to elicit high immune responses, forming an inhibitor binding to immune cells which recognize invaders, prime them and alter their memories. It also helps to transfer the genetic component which is an active molecule called integrase inhibitor and coat protein inhibitor from nucleus to cytoplasm containing Endoplasmic Reticulum (ER) which is a major site of drug metabolism. The MRNAS is triggered by the drug to form a template for protein synthesis, which synthesizes the active molecule of the drug along.

The active molecule of the drug, Fungocyneo F & B, contains an inhibitor, which acts on genetic component of Human Immune Virus (HIV). HIV uses MRHAS to copy it's genes into the DNA₁ using it own reverse transcriptase inhibitor to transcribe the genetic component of Human DNA which re-interprets the viral genome. In this case, various useful genes cannot be produced while the immune components are impaired in the process. This gives room to opportunistic infections (OIS) to set in and multiply sporadically. The strands of impaired DNA now form a template for production of daughter virus. The drug's active molecule is called "Viracomb Irreversible Inhibitor" (VII). This is a molecule that can reproduce itself in association with carbon and proteins, traveling along with MRNAS which carries the genetic information of this molecule into the cytoplasm and endoplasmic reticulum where metabolism of the drug further takes place in connection with auxiliaries protein and carbon which form basis for new cellular development containing the ^RVU Viracomb Irreversible Inhibitor to alter the viral genome and remain an immune component that recognizes invading virus; it primes and alters their binding with receptor cell. The usefulness and function of VII in the gastro intestinal tracts is that it triggers production of amino acids in sufficient amount so that enzymes and cell membranes which are impaired during HIV developments into AIDS are repaired when various enzymes are reformed.

Accordingly, the drug and the composition according to the invention are more particularly intended for administration to human being or animals for therapeutics and prophylactics treatment using in-vivo and in-vitro method as parameters; intramuscular and oral particularly for treatment of viral infections, protozoa and diabetes.

This drug is easily binding to various cells and blood plasma effecting quick cellular re-development. An inhibitor of HIV protein coat.

DETAIL OF MORPHOLOGY AND GENERAL PROPERTIES

Details of morphology and general properties are given in the following: 1. MORPHOLOGY AND DISCOVERY OF COMPONENT

Active substance: TYP.1 , A & B protein and carbon is an extract of a particular organic plant called Topica lgboemma newly discovered in Nigeria by the inventor. The discovery of the active molecule was a result of serious and rigorous scientific study of this molecule in rodents. The studies and discovery started from a point where a particular rodent was entrapped but because of the sores and symptoms looked like some opportunistic infections related to HIV was discovered, the rodent was set free. Surprisingly, the rodent survived the symptoms of leukemia virus, visna virus, nose and skin rashes. This is the point where the inventor needed to research into what must have happened. Luckily, I discovered the presence of this plant in its hole under a palm-tree where I set the trap and I also discovered the stem of the particular tree very close to the whole. There was a mark of the rodent's teeth on the stem. The same fruits I found in the hole were the same with the one found on the tree with teeth-mark. The plants found in the hole and the ones found outside were subjected to phytochemical analysis to be sure that the components are the same. Below is the analysis: (1) ALKALOIDS TEST

Dragenduff's Meyer s Wagner's

PLANT I - tve - tve - tve

PLANT Il - tve - tve - tve

(2) CARDENOLIDES TEST

Kellerkilliani Kedde

PLANT I - tve - tve

PLANT Il - tve _— tve

(3) ANTHRAQUINONES TEST

Chloroform Ammonia PLANT I - tve

PLANT Il - tve

(4) SAPONINS TEST

Frothing

PLANT I tve

PLANT Il tve

(5) TANNINS TEST

FERRIC CHLORIDE

PLANT I tve

PLANT Il tve

With these analyses I was double sure that I had got the right components.

Another observation was that the presence of a single strand molecule was discovered through re-culturing in rat where I discovered that the strange molecule was actually the active molecule because combinations of the different plants with single strain of these phytochemicals was cultured but could not re-synthesize itself like the original plant in groups of wild mammals. The active molecule was isolated in grain carbon and animal protein. Another point was that, combination of: anthraquinones, cardenolides, saponin, alkaloid and tannin does not produce the effect of Tropica Igboemma. HPLC and AAS analyses were done to determine colour and differences of the molecules.

(2) THE DPD PROTEIN USED FOR ADHESION TEST: Through my father, I discovered that diplopod (dpd) proteins are very useful as a mild vaccine against rabies virus. Further scientific studies showed me that they are useful also as vaccine against malaria. Studies were carried out in dogs to know the dose, efficacy and duration of the effects of these dpd proteins.

A dog called Tiger was used as a case study, although my father had been practicing this before I was born in a situation where they cultured diplopod protein in dogs' mouth to prevent infections because forest was the home of rabid virus and it is organic.

This method was adopted to: (i) prevent the hunted animal from rabid infection when eaten by human (ii) to prevent man in course of accident with the dogs teeth. The efficacy of this inspiration was determined by injecting some dogs with the serum of a dog that was infected into the hunting dog. Some were vaccinated with millipede while the other dogs were not prevented. The amazing result was that, the four dogs that were unprotected developed symptoms of rabies within two years before they died.

Moreover, the saliva form vaccinated dog is also used to vaccinate the young dogs and they always survived till death without any symptoms of rabies, but the free ones on hunting game do not always survive rabies for 1 year.

1. I would have concluded that this protein can act as permanent vaccine against HIV but certain things were considered. These are:

(i) HIV was not a single strain of organic virus but a co

(ii) mbination of other viral strains (Retro Virus), (ii) HIV uses DNA as mechanism for replication.

In these case, the method of using the protein does not work by binding it to plasma, lymphocytes and T-cell. It is strong and doesn't expire quickly. It is a very good envelope for the active chemical when combined with auxiliary carbon of Anchomanes diffomis where it synthesizes and helps the molecules to re-interpret itself faster. An oral test was conducted to know this development compare to grain starch and protein which takes long time and the sugar contents of grain starch may be bad. Again, the active molecule uses the protein to initiate the body protein responses to produce antibody since the active molecule re-syntheses itself and the millipede protein itself is an antigen and it quickly copies the organic molecule i.e. active, when culture in it and are complementary to each other.

Moreover, the serum of the said Animal contains: (i) mild gram positive bacteria, (ii) mild protozoa e.g. P. falceparum type These are present in the protein of this animal and are neutralized by the active auxiliary extract called Anthoclesta carbon; subjected to a very serious sterile condition of about 80°c in an autoclave machine ZDX-40 after addition of chemical folmadehydrade which is vapourised by formalin vapourizer to render it non-toxic. COMBINATION OF GENERAL PROPERTIES

Anthoclesta carbon + anchomanes carbon + TYP. I, A & B's P & C + DPD's P & C, whereas TYP - I, A & B, PC means Tropica lgboemma A & B types of protein and carbon, DPD & P & C means Diplopoda Carbon and protein. These components are combined to produce viracomb injection and pills which chemical name is called or titled (Vicoe-loz-araceae).

Find below analysis for weight and percentage of each component:

1. TYP - 1- A & B, C & P = 370mg - 50%/100

2. Antho-C-123mg= 16.6%/100

3. Ancho-C-123mg = 16.6%/100

4. DPD-C & P = 123 mg = 16.6%/100 Total weight = 740mq

100%

(i) The TYP-I-A & B C & P extraction is done by grinding the parent materials into powder and dissolve in water to be filtered with sediment tank attached with micro filtering apparatus. After these, the liquid obtained is taken into centrifuge machine to remove the other sediment.

Types of centrifuge: Bechman Coulter option L-100 x P Ultracentrifuge, with speed of 40^m/_s; Temperature: 35°c, refrigerated capacity of +0.5°c

Moreover, the filtered liquid is also taken into large capacity freezing dryer which will convert the liquid into a soluble solid taken into large capacity oven under a serious heating temperature of 60°c to obtain a pure dried soluble powder. Type of oven (Genlab equatron, lso 9001 ). This method is adopted in auxiliary components Antho. C and Ancho C. (ii) The Diplopoda protein is also obtained through grinding and micro filtering machine and subjected to the same method of obtaining substance A with the difference of chemical formadehydrate. The formadehydrate used to sterilize and neutralize is evaporated and removed through formalin vaporizing machine.

The component is weighed according to their useful proportion with AR 1530 analytical balance 150.0.0019. Autoclave ZDX-40 and sterilizer is also used to sterilize the powder under a safe condition of 80°c. The three components according to their relevant weight is mixed in 750 mg plastic blender. Preservative is Benzyl Alcohol.

Adhesion

Adhesion to various enzymes and receptors cells are compared to adhesion of Human Immune Virus to receptor cells, DNA and enzyme but the active molecule easily binds to receptor cells with a type of inhibitors which is different from Human Immune Virus; it is stronger and alters genetic components of the virus, e.g. the protein coat, integrase and reverse transcriptase (he viral general metabolism).

This drug metabolizes and catabolyses the production of new MRNAS molecule containing a gene called Viracomb Inhibitors which is carried by MRNA from nucleus to cytoplasm where it acts as template for protein synthesis and is circulated round the body through endoplasmic reticulum. The MRNAS of HIV is not synthetic but borrowed from the replicating or developing DNA, while MRNAS produced by viracomb is synthetics and can use any other auxiliary protein or carbon from intestinal tract to produce various enzymes needed for building a new DNA.

DISPLACEMENT To determine the ability of the active molecule and displacement characteristics, the composition of the invention is done to displace the pathogen called HIV. The extent to which it is capable of displacing viral genome, adhering to receptor cell is examined below:

To this end, a solution of TYP-I- A & B, C & P 40 mg is administered interperitoneally in order to culture and measure the rate of efficacy in rat e.g. Wister rat and Swiss albino rat of variant body weight of 128.4 - 210.Og and 14.0 - 18.Og. The active substance was found to have increased the production of BHI enzymes which removes the skin, rashes, nose rashes, construction and palpitation; increased the weight from 123.4, 21Og which was the weight of the animal after 4 months infection of the Wister rats to 138.4g & 223.Og. Moreover, the 40mg of the active substance increased the concentration of the drugs in the animals after cross examination of the animal's blood to an extent that the properties of the active drug reflect in all the animal cells. This was compared by nuclear magnetic resonance machine. 40mg active substance increased to 600mg as synthesized in the experimental animals. However, in human volunteer where DNA Test of HIV 1 & 2 was positive with the following examination and report: CD4 count - 500 cell/mm³, lymphocytes 1200mm/³ with symptoms as in experimental rat above. 750mg of Viracomb was administered twice over 48 hourly administration. Test reveals the CD4 count increasing from 500-640 within two months, lymphocytes (WBC) increasing from 1200mm/³ - 2,400mm/³' and weight increased from 50kg - 75kg.

Efficacy of the Viracomb

The latest attempt of scientists is to find a solution that can retain (i) the volume of lymphocytes capable of countering infections; (ii) Production of langerin on receptor cell surface, containing vaccine properties, inhibiting coat proteins. This what the new invention, Viracomb vaccine, does.

There were a few healthy volunteers with similar parameters as above, yet they do not have rashes, persistent head-aches, which were symptoms of HIV even though their spouses had been infected.

They were placed on the displacement test by administering 500mg on hourly administration over 2, whereas estimated doses is IOOOmg on prophylaxis. In cases of full blown AIDS, intramuscular administration of Viracomb is 750mg x 7/48 hourly, in addition to oral dosage of 740mg x 4 twice daily for 92 days. Total dose is 544,640mg for total cure.

Claims

(1) A prophylactic and therapeutic (cure and vaccine) method of treating viruses especially human immune virus (HIV/AIDS) comprising administering intravenously, intramuscularly and orally to human in need thereof of ViracombTM (Vicoe-loz-Araceae), effective amount of composition containing in combination with an ingestible support, a sterilized combined group of carbon from the carbon and protein from organic plants Tropica lgboemma from which the active molecule, Fungocyneo F & B, is taken; anthoclesta, anchomanes and diplopoda protein with it's carbon isolated according to their useful proportion.

(2) A method according to claim 1 wherein composition is in forms of tablet, capsules etc in different weights for oral consumption and administration containing legume protein and grain carbon.

(3) A method according to claim 1 wherein composition is in form of soluble powder, soluble in distilled water for injection for intramuscularly and intravenous administration wherein it comes in different weights, sealed in either transparent bottle or ample for prophylactic and therapeutic treatment of malaria and protozoan diseases, hepatitis B and hepatitis C

(4) A method according to claim 1 wherein composition is in form of isotonic crystal liquid in sealed bottle of different sizes as injection for treatment of amylase deficiency causing skin diseases; boosting, BHI enzymes which control skin diseases in human and animals, prevention and vaccines against rabies virus.

(5) A method according to claim 1 wherein the composition of active compound with a proportion of legume protein is in tablet form for treatment of diabetes.

(6) A method according to claim 1 wherein the composition is only 500mg of Fungocyneo F & B with DPD protein in form of soluble permeable crystal liquid sealed in sterile bottle for the treatment of diabetes through intramuscular route.

(7) A method according to claim I wherein the composition and the discovery of usefulness of parent materials and untitled name is titled and credited to the inventor.

(8) A method according to claim one wherein, 5Q0mg of anthoclesta is in tablet form or injection form for stepping down of over secretion of Adrenalin hormones and palpitation.

(9) A method according to claim 1 wherein the active substance in any form without combination of the auxiliaries is used to step up adrenalin hormones and to cure gastro intestinal disorders.